Skip to content

G&A at other companies

Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$10.45M+13.9%
TRV
Trevi Therapeutics, Inc.TRVI
$4.97M+35.9%
PVL
Palvella TherapeuticsPVLA
$5.52M+45.4%
AdaptHealth logo
AdaptHealthAHCO
$95.91M+10.4%
Moderna logo
ModernaMRNA
$173M-18.4%

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's G&A?
Savara (SVRA) reported G&A of $15.57M in Q1 2026.
How has Savara's G&A changed year-over-year?
Savara's G&A increased by 68.4% year-over-year, from $9.25M to $15.57M.
What is the long-term trend for Savara's G&A?
Over 4 years (2021 to 2025), Savara's G&A has grown at a 35.8% compound annual growth rate (CAGR), from $12.35M to $42.06M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.